Compile Data Set for Download or QSAR
maximum 50k data
Found 50 Enz. Inhib. hit(s) with all data for entry = 912
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US10123984, Example 2H | US10744104, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298298(US10123984, Example 5-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298308(US10123984, Example 8-3 | US10744104, Example 8-3 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298307(US10123984, Example 8-2 | US10744104, Example 8-2 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298306(US10123984, Example 7B | US11547687, Example 7B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US10123984, Example 6A | US10744104, Example 6A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298304(US10123984, Example 5-17 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298303(US10123984, Example 5-15)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298302(US10123984, Example 5-14)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298301(US10123984, Example 5-13 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298300(US10123984, Example 5-9 | US20230285340, Example 5...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298299(US10123984, Example 5-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298322(US10123984, Example 14A | US10123984, Example 14C ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US10123984, Example 2A | US10744104, Example 2A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298291(US10123984, Example 2N | US11547687, Example 2N | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US10123984, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US10123984, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(BDBM582703 | US10123984, Example 3A | US10123984, ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(BDBM582703 | US10123984, Example 3A | US10123984, ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US10123984, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298317(US10123984, Example 11-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298310(US10123984, Example 8-5)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298309(US10123984, Example 8-4 | US20230285340, Example 8...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298297((2R,4R)-5-(3-Chlorobiphenyl-4-yl)-2-hydroxy-4-(oxa...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298315((2S,4R)-5-(3'-Fluorobiphenyl-4-yl)-2-hydroxymethyl...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298289(US10123984, Example 2I | US10744104, Example 2I | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298287(US10123984, Example 2G | US10744104, Example 2G | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298316(US10123984, Example 11-1 | US10744104, Example 11-...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298319(US10123984, Example 11-4 | US10744104, Example 11-...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298321((R)-3-[N-(3′-Chlorobiphenyl-4-ylmethyl)-N...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298322(US10123984, Example 14A | US10123984, Example 14C ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298312(US10123984, Example 9A | US10744104, Example 9A | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298326(US10123984, Example 16 | US10744104, Example 16 | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298322(US10123984, Example 14A | US10123984, Example 14C ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298327(US10123984, Comparative Compound A )
Affinity DataKi:  6.31nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298328(US10123984, Comparative Compound B)
Affinity DataKi:  6.31nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298284((R)-5-Biphenyl-4-yl-2-hydroxy-4-(oxalylamino)penta...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298325((2R,4S)-5-Biphenyl-4-yl-2-hydroxy-5-methyl-4-(oxal...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298318(US10123984, Example 11-3 | US10744104, Example 11-...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298320(3-(N-Biphenyl-4-ylmethyl-N′-oxalylhydrazino)...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298290(US10123984, Example 2J | US10744104, Example 2J | ...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298311(US10123984, Example 8-6)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034842((2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50:  5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034846((2R,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50:  27nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034854((2R,4S)-5-Biphenyl-4-yl-4-(4-carboxy-butyrylamino)...)
Affinity DataIC50:  90nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298276(US10123984, Compound 21g)
Affinity DataIC50:  92nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034868((2S,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50:  190nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034857((2R,4S)-5-Biphenyl-4-yl-4-(5-carboxy-pentanoylamin...)
Affinity DataIC50:  324nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034865((2S,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50:  700nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In DepthDetails US Patent